ULTIMOVACS AS has a total of 13 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2011. It filed its patents most often in United States, EPO (European Patent Office) and Australia. Its main competitors in its focus markets pharmaceuticals, biotechnology and foods and drinks are ICONIC THERAPEUTICS INC, PLATELET TARGETED THERAPEUTICS LLC and APPLIED MOLECULAR TRANSP INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 4 | |
#2 | EPO (European Patent Office) | 2 | |
#3 | Australia | 1 | |
#4 | Canada | 1 | |
#5 | China | 1 | |
#6 | Japan | 1 | |
#7 | Republic of Korea | 1 | |
#8 | Serbia | 1 | |
#9 | WIPO (World Intellectual Property Organization) | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Foods and drinks |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Peptides | |
#3 | Therapeutic chemical compounds | |
#4 | Enzymes | |
#5 | Microorganisms |
# | Name | Total Patents |
---|---|---|
#1 | Gaudernack Gustav | 12 |
#2 | Suso Else Marit Inderberg | 7 |
#3 | Rasmussen Anne-Marie | 6 |
#4 | Tornes Audun | 5 |
#5 | Rasmussen Anne Marie | 1 |
#6 | Anne-Marie Rasmussen | 1 |
#7 | Else Marit Inderberg Suso | 1 |
#8 | Gustav Gaudernack | 1 |
Publication | Filing date | Title |
---|---|---|
CA3026172A1 | A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer |